Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06511505 · ClinicalTrials.gov registry record · NA
NOrthwestern Tempus AI-enaBLed Electrocardiography (NOTABLE) Trial
A NA study, sponsored by Northwestern University.
- Not yet
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
NCT06511505: Clinical Trial NA study, sponsored by Northwestern University.
NCT06511505 is a NA study that has not yet begun recruiting, run by Northwestern University. The registered enrollment target is 1,000 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06511505, a NA study, has not yet begun recruiting, sponsored by Northwestern University.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to determine if a machine learning/artificial intelligence (AI)-based electrocardiogram (ECG) algorithm (Tempus Next software) can identify undiagnosed cardiovascular disease in patients. It will also examine the safety and effectiveness of using this AI-based tool in a clinical setting. The main questions it aims to answer are: 1. Can the AI-based ECG algorithm improve the detection of atrial fibrillation and structural heart disease? 2. How does the use of this algorithm affect clinical decision-making and patient outcomes? Researchers will compare the outcomes of healthcare providers who receive the AI-based ECG results to those who do not. Participants (healthcare providers) will: Be randomized into two groups: one that receives AI-based ECG results and one that does not. In the intervention group, receive an assessment of their patient's risk of atrial fibrillation or structural heart disease with each ordered ECG. Decide whether to perform further clinical evaluation based on the AI-generated risk assessment as part of routine clinical care.
Primary Outcome
Number of participants with a new diagnosis of atrial fibrillation, identified by ICD-10-CM diagnosis code entry in the electronic health record (EHR), among patients ≥65 years old without a prior AF diagnosis who received a 12-lead ECG as part of routine clinical care.
Interventions
- OTHER TEMPUS AI-enabled ECG-based Screening Tool
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-08-03 |
| Est. Completion | 2026-02-03 |
| Phase | NA |
What is known before NCT06511505 opens enrollment
NCT06511505 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 1 intervention - of which TEMPUS AI-enabled ECG-based Screening Tool is the first listed.
NCT06511505 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06511505 about?
NCT06511505 is a clinical study titled "NOrthwestern Tempus AI-enaBLed Electrocardiography (NOTABLE) Trial". The goal of this clinical trial is to determine if a machine learning/artificial intelligence (AI)-based electrocardiogram (ECG) algorithm (Tempus Next software) can identify undiagnosed cardiovascular disease in patients. It will also examine the safety and effectiveness of using this AI-based tool...
What is the current status of trial NCT06511505?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2024-08-03. Estimated completion is 2026-02-03.
What interventions are being tested in trial NCT06511505?
The interventions under investigation include: TEMPUS AI-enabled ECG-based Screening Tool (OTHER).
Who is sponsoring clinical trial NCT06511505?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06511505's enrollment target sits among peer trials
1,000 107th of 2000 higher than 1,880 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI